Efficacy of botulinum neurotoxin-A in the treatment of neuropsychiatric symptoms in patients with Parkinson’s disease: an open-label randomized controlled study
This study demonstrates the potential of BTX-A in alleviating tension, anxiety, depression, sensitivity, and other neuropsychiatric symptoms in PD patients. Importantly, BTX-A's efficacy was comparable to that of citalopram, suggesting its potential as a viable therapeutic option for managing neuropsychiatric manifestations in PD.
Authors
- Ming Wei (ORCID: https://orcid.org/0000-0001-5235-1281)
- Jun Shen (ORCID: https://orcid.org/0000-0001-7206-1847)
- Hui Wang (ORCID: https://orcid.org/0000-0002-7639-5702)
- Xiu Yang
- Qiu Han
- Xiaofeng Zhu (ORCID: https://orcid.org/0009-0000-1745-2271)
Institutions
- Xuzhou Medical College (CN)
- Huaian First People’s Hospital (CN)
- Second People’s Hospital of Huai’an (CN)
- Nanjing Medical University (CN)
Publication Details
- Journal
- Expert Review of Neurotherapeutics
- Published
- 2025-05-06
- DOI
- https://doi.org/10.1080/14737175.2025.2500753
- Citations
- 1
- Primary Topic
- Parkinson's Disease Mechanisms and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.39